Calyxt Inc (NASDAQ:CLXT) CEO James Blome Sells 2,902 Shares of Stock
Calyxt Inc (NASDAQ:CLXT) CEO James Blome sold 2,902 shares of Calyxt stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.01, for a total value of $14,539.02. Following the transaction, the chief executive officer now owns 198,057 shares in the company, valued at $992,265.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
James Blome also recently made the following trade(s):
- On Wednesday, July 1st, James Blome sold 3,495 shares of Calyxt stock. The stock was sold at an average price of $4.65, for a total value of $16,251.75.
NASDAQ:CLXT opened at $4.41 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 8.80 and a current ratio of 9.38. The stock’s 50-day simple moving average is $4.90 and its 200 day simple moving average is $4.85. The company has a market cap of $152.32 million, a P/E ratio of -3.34 and a beta of 2.41. Calyxt Inc has a 52-week low of $2.40 and a 52-week high of $9.77.
CLXT has been the topic of several recent analyst reports. BMO Capital Markets lowered Calyxt from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $13.00 to $7.00 in a report on Friday, May 8th. Wells Fargo & Co dropped their price target on Calyxt from $6.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Friday, May 15th. National Securities reissued a “buy” rating and issued a $10.00 price target on shares of Calyxt in a research note on Friday, May 8th. Canaccord Genuity began coverage on Calyxt in a research note on Tuesday. They issued a “buy” rating and a $8.00 price target on the stock. Finally, Zacks Investment Research downgraded Calyxt from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Calyxt presently has an average rating of “Hold” and an average price target of $6.88.
Several large investors have recently added to or reduced their stakes in CLXT. Oppenheimer & Co. Inc. acquired a new stake in shares of Calyxt in the first quarter valued at about $47,000. Two Sigma Investments LP acquired a new stake in shares of Calyxt in the first quarter valued at about $61,000. Bank of New York Mellon Corp increased its position in Calyxt by 15.8% during the first quarter. Bank of New York Mellon Corp now owns 26,097 shares of the company’s stock worth $86,000 after buying an additional 3,563 shares during the last quarter. UBS Group AG increased its position in Calyxt by 40.4% during the fourth quarter. UBS Group AG now owns 14,296 shares of the company’s stock worth $100,000 after buying an additional 4,116 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Calyxt by 26.9% during the first quarter. Wells Fargo & Company MN now owns 45,933 shares of the company’s stock worth $153,000 after buying an additional 9,733 shares during the last quarter. 23.93% of the stock is currently owned by institutional investors and hedge funds.
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes.
Recommended Story: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.